1496 TESTOSTERONE TREATMENT AFTER RADICAL PROSTATECTOMY FOR PATHOLOGICALLY ORGAN-CONFINED PROSTATE CANCER; RESULTS FROM A MULTI-INSTITUTIONAL STUDY

Hendrik Isbarn, Margit Fisch, Hartwig Huland, Markus Graefen, Frank SommerThe Journal of Urology 2010 · DOI

Abstract

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy II1 Apr 20101496 TESTOSTERONE TREATMENT AFTER RADICAL PROSTATECTOMY FOR PATHOLOGICALLY ORGAN-CONFINED PROSTATE CANCER; RESULTS FROM A MULTI-INSTITUTIONAL STUDY Hendrik Isbarn, Margit Fisch, Hartwig Huland, Markus Graefen, and Frank Sommer Hendrik IsbarnHendrik Isbarn More articles by this author , Margit FischMargit Fisch More articles by this author , Hartwig HulandHartwig Huland More articles by this author , Markus GraefenMarkus Graefen More articles by this author , and Frank SommerFrank Sommer More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1233AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES For several decades, testosterone treatment (TT) in patients with a history of prostate cancer (PCa) was invariably contraindicated. Recently, data emerged indicating that TT might not be harmful to patients, who are successfully cured of their disease. However, all of the currently available studies are limited due to small sample sizes and relatively short follow-up. Our objective was to evaluate the biochemical recurrence (BCR) rate in patients who received TT after radical prostatectomy (RP) in a multi-institutional fashion. METHODS We conducted a survey among urologists from all parts of Germany. The colleagues were queried, whether they treat patients suffering from symptomatic hypogonadism with TT after RP, and, in case of suitable patients, to provide us with the respective data. We examined the BCR rate in this patient cohort. RESULTS At present, our study cohort comprises data from 69 men who incessantly receive TT after RP for a minimum duration of 6 months. Median age at start of TT was 56 years. All patients had organ-confined disease at RP, negative surgical margins, were not exposed to adjuvant therapy, and had an undetectable PSA-level (<0.1 ng/ml) at initiation of TT. Median testosterone level at start of TT was 2.9 ng/dL and the earliest TT started in 2003. Median time from RP until beginning of TT was 24 months. After a median follow-up of 19 months (range: 6-72), none of the patients has evidence of BCR. CONCLUSIONS Our data suggest that TT can be offered to well selected patients apparently cured of their PCa, without compromising cancer control outcomes. While randomized controlled trials are currently lacking, this study is another piece of evidence that TT in patients with a PCa history is not as harmful as was believed for several decades and should encourage urologists to offer TT to symptomatic hypogonadal patients with successfully treated organ-confined PCa. Hamburg, Germany© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e576-e577 Peer Review Report Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hendrik Isbarn More articles by this author Margit Fisch More articles by this author Hartwig Huland More articles by this author Markus Graefen More articles by this author Frank Sommer More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
BibTeX
@article{isbarn2010testosterone,
  author = {Hendrik Isbarn and Margit Fisch and Hartwig Huland and Markus Graefen and Frank Sommer},
  title = {{1496 TESTOSTERONE TREATMENT AFTER RADICAL PROSTATECTOMY FOR PATHOLOGICALLY ORGAN-CONFINED PROSTATE CANCER; RESULTS FROM A MULTI-INSTITUTIONAL STUDY}},
  journal = {The Journal of Urology},
  year = {2010},
  doi = {10.1016/j.juro.2010.02.1233},
}

Loading related content...

Figure